This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Annexin A2 (ANXA2)	<p>Patient sample, mouse and cell culture studies suggest inhibiting ANXA2 could help treat NSCLC. In human NSCLC samples, ANXA2 levels were greater than those in healthy lung tissue and correlated with poor overall survival. In mice injected with human NSCLC cells, small hairpin RNA against ANXA2 decreased tumor growth compared with control shRNA. In cultured NSCLC cells, small interfering RNA against ANXA2 increased tumor suppressor p53 levels and cell-cycle arrest compared with scrambled siRNA. Next steps include determining other physiological effects of inhibiting ANXA2.</p> <p>SciBX 5(33); doi:10.1038/scibx.2012.864 Published online Aug. 23, 2012</p>	Findings unpatented; licensing status not applicable	<p>Wang, C.-Y. <i>et al. J. Biol. Chem.</i>; published online Aug. 2, 2012; doi:10.1074/jbc.M112.351957</p> <p>Contact: Chiou-Feng Lin, National Cheng Kung University, Tainan, Taiwan e-mail: cflin@mail.ncku.edu.tw</p>